BeOne Medicines won US accelerated approval for its sonrotoclax (BCL2 inhibitor) in a rare, aggressive blood cancer setting where Venclexta is used off-label. The regulatory move establishes BeOne’s position in the ongoing effort to broaden treatment options for patients with difficult-to-treat hematologic malignancies. The approval adds to the growing competitive pressure around BCL2-pathway targeting, as companies continue to refine patient selection and dosing strategies to achieve durable responses while managing safety tradeoffs.